{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T13:33:26Z","timestamp":1768743206981,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Diffuse Lung Diseases Research Group from the Ministry of Health, Labour, and Welfare"},{"name":"National Hospital Organization, Japan"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","respiratoryinvestigation.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.resinv.2013.09.002","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T17:02:18Z","timestamp":1382634138000},"page":"136-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"52","author":[{"given":"Toru","family":"Arai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunobu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikatoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Akira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kitaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2013.09.002_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","article-title":"Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis","volume":"157","author":"Bjoraker","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1164\/ajrccm.149.2.8306044","article-title":"Determinants of survival in idiopathic pulmonary fibrosis","volume":"149","author":"Schwartz","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1183\/09059180.00001012","article-title":"Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis","volume":"21","author":"G\u00fcnther","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2013.09.002_bib4","first-page":"367","article-title":"Effects of pirfenidone on transforming growth factor-b gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.resinv.2013.09.002_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1164\/ajrccm.159.4.9805017","article-title":"Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study","volume":"159","author":"Raghu","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib6","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2169\/internalmedicine.41.1118","article-title":"Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis","volume":"41","author":"Nagai","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2013.09.002_bib8","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2013.09.002_bib9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/rccm.200708-1271OC","article-title":"Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan","volume":"177","author":"Inoue","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2013.09.002_bib14","series-title":"Idiopathic interstitial pneumonia: diagnosis and treatment","author":"The Japanese Respiratory Society","year":"2011"},{"key":"10.1016\/j.resinv.2013.09.002_bib15","series-title":"Interstitial lung disease","first-page":"895","article-title":"Idiopathic pulmonary fibrosis","author":"King","year":"2011"},{"key":"10.1016\/j.resinv.2013.09.002_bib16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. American Thoracic Society and European Respiratory Society","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1465-9921-12-143","article-title":"Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefit from treatment","volume":"12","author":"Azuma","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2013.09.002_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2013.09.002_bib19","article-title":"CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis","author":"Iwasawa","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.resinv.2013.09.002_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-12-93","article-title":"The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial","volume":"12","author":"Taniguchi","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2013.09.002_bib21","first-page":"405","article-title":"Ameliorative effects of mosapride or Rikkunshi-to on the suppression of gastrointestinal motility by pirfenidone","volume":"40","author":"Itoh","year":"2012","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1016\/j.resinv.2013.09.002_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1756283X10362639","article-title":"Functional dyspepsia","volume":"3","author":"Brun","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.resinv.2013.09.002_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1540\/jsmr.46.1","article-title":"Duodenal hypersensitivity to acid in patients with functional dyspepsia-pathogenesis and evaluation","volume":"46","author":"Ishii","year":"2010","journal-title":"J Smooth Muscle Res"},{"key":"10.1016\/j.resinv.2013.09.002_bib24","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3748\/wjg.v18.i13.1517","article-title":"Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia","volume":"18","author":"Sakaguchi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.resinv.2013.09.002_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.resinv.2013.09.002_bib26","unstructured":"Esbriet: EPAR-Product Information. \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002154\/WC500103049.pdf. 07\/02\/2012\u3009."},{"key":"10.1016\/j.resinv.2013.09.002_bib27","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.112.045575","article-title":"Evaluation of six proton pomp inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome 2C19","volume":"40","author":"Zvyaga","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.resinv.2013.09.002_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/0049825021000023978","article-title":"Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+\/K+-ATPase inhibitors and other xenobiotics","volume":"33","author":"Krusekopf","year":"2003","journal-title":"Xenobiotica"},{"key":"10.1016\/j.resinv.2013.09.002_bib29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2125.1999.00043.x","article-title":"Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline","volume":"48","author":"Dilger","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.resinv.2013.09.002_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/00003088-200140070-00004","article-title":"Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole","volume":"40","author":"Andersson","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.resinv.2013.09.002_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0009-9236(99)70129-3","article-title":"Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists","volume":"65","author":"Martinez","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.resinv.2013.09.002_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2036.1999.00021.x","article-title":"Review article: drugs interactions with agents used to treat acid-related disease","volume":"13","author":"Humphries","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.resinv.2013.09.002_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00365528709090142","article-title":"Famotidine: a notable lack of drug interactions","volume":"134","author":"Humphries","year":"1987","journal-title":"Scand J Gastroenterol Suppl"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534513001287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534513001287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T10:51:11Z","timestamp":1539255071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534513001287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S2212534513001287"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2013.09.002","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Japanese Respiratory Society. Published by Elsevier Japan KK","name":"copyright","label":"Copyright"}]}}